VectivBio announces closing of USD 54m aggregate financing
VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a Swiss head-quartered clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announces it has closed each of its previously announced public offering of 6,467,688 ordinary shares, including the sale to the underwriters of 752,688 ordinary shares sold pursuant to the partial exercise of the underwriters’ previously granted option to purchase additional ordinary shares and its previously announced private placement for the sale of 3,478,260 ordinary shares to Forbion’s Growth Opportunities Fund II. All ordinary shares sold in the public offering were offered by VectivBio at a public offering price of USD 5.25 per share. The total gross proceeds to VectivBio from the public offering, including pursuant to the underwriters’ option, were approximately USD 34 million, before deducting underwriting discounts and commissions and offering expenses. All ordinary shares sold in the private placement transaction were offered by VectivBio at a price of USD 5.75 per ordinary share, for gross proceeds to VectivBio of approximately USD 20 million, before deducting financial advisory fees and other offering expenses.
SVB Securities and Piper Sandler acted as joint book-running managers for the public offering. LifeSci Capital acted as a co-manager for the public offering. SVB Securities, Piper Sandler and LifeSci Capital also acted as financial advisors for the private placement transaction.
NKF acted as Swiss counsel to SVB Securities, Piper Sandler and LifeSci Capital in the public offering. The NKF team was led by Capital Markets partners Philippe Weber and Thomas Brönnimann, working with senior associate Samuel Hochtrasser (Capital Markets) and tax partner Markus Kronauer.